Answer
The most frequently reported adverse reactions to reslizumab are increased blood creatine phosphokinase (approximately 2% of patients) and anaphylactic reaction (less than 1% of patients).
Sources for this answer
- Cinqaero (reslizumab) 10 mg/mL concentrate for solution for infusionTeva Pharmaceuticals Ltd · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked